Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Acute Lymphoblastic Leukemia (ALL): early-phase trial registry
4 of 17 indexed Acute Lymphoblastic Leukemia (ALL) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,004 of 28,707 conditions by registered trial count.
17 US clinical trials · 4 currently recruiting · #1,004 of 28,707 conditions by registered trial count
Acute Lymphoblastic Leukemia (ALL): 17 US clinical trials tracked, 4 recruiting.
Acute Lymphoblastic Leukemia (ALL) is the subject of 17 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most active sponsor is St. Jude Children's Research Hospital, running 4 of these trials.
Enrollment posture brief
Registry condition acute-lymphoblastic-leukemia-all
OPEN 4 | RECR 24% | LATE 1 | EARLY 11 | RANK #1004 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Cataract (24% recruiting · 85 trials)
Acute Lymphoblastic Leukemia (ALL) lists 4 open slots (24% of 17 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Acute Lymphoblastic Leukemia (ALL) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Acute Lymphoblastic Leukemia (ALL) is recruiting below its size-band peers.
4 of 17 indexed trials (23.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Acute Lymphoblastic Leukemia (ALL) research.
St. Jude Children's Research Hospital accounts for 4 of 17 trials (23.5%). 14 distinct sponsors appear on at least one study for this condition label.
-
Most Acute Lymphoblastic Leukemia (ALL) trials plan to enrol fewer than 100 people.
Median target enrolment is 54 among the 17 trials that report a genuine target (sentinel values excluded). 14 of those (82.4%) plan for fewer than 100 participants.
-
Acute Lymphoblastic Leukemia (ALL) research is mostly interventional.
16 interventional and 1 observational studies make up this index (94.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
17 total, page 1 of 1
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Center for International Blood and Marrow Transplant Research
NCT01351545
Bright Ideas - CIN Feasibility Study
The Hospital for Sick Children
NCT04929899
Cord Blood Transplant in Adults With Blood Cancers
Memorial Sloan Kettering Cancer Center
NCT05884333
Transcutaneous Auricular Vagus Nerve Stimulation for Insomnia in Survivors of Childhood Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital
NCT07191119
Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
St. Jude Children's Research Hospital
NCT02790515
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
St. Jude Children's Research Hospital
NCT03849651
Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT
Baylor College of Medicine
NCT00840853
Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL
Dana-Farber Cancer Institute
NCT03740334
CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
Diane George
NCT02061800
Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
Amgen
NCT02303821
Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia
Spectrum Pharmaceuticals
NCT00495079
Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study
Novartis Pharmaceuticals
NCT01735955
Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM
Gamida Cell
NCT01816230
Reduce Sedentary Time in Acute Lymphoblastic Leukemia
Children's Hospital Los Angeles
NCT06182163
Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome
St. Jude Children's Research Hospital
NCT02212561
Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit
Fate Therapeutics
NCT01527838
Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders
Massachusetts General Hospital
NCT01758042
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 4 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Acute Lymphoblastic Leukemia (ALL) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Acute Lymphoblastic Leukemia (ALL) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Acute Lymphoblastic Leukemia (ALL) page
17 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Acute Lymphoblastic Leukemia (ALL) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- St. Jude Children's Research Hospital sponsors the most Acute Lymphoblastic Leukemia (ALL) trials on record, review their full trial history before evaluating a specific study. See St. Jude Children's Research Hospital's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Acute Lymphoblastic Leukemia (ALL) condition card totals 17 registered trials; most-linked intervention Cyclophosphamide; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.